Dr. Reddy’s Laboratories Ltd ADR

Dr. Reddy's Laboratories is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products including active pharmaceutical ingredients (APIs), generic formulations, branded generics, biosimilars, and over-the-counter (OTC) products. The company operates across major therapeutic areas including gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Its business is organized into two primary segments: Global Generics, which encompasses branded and unbranded generics, biosimilars, and OTC products across North America, India, Emerging Markets (including Russia, CIS, and Rest of World), and Europe (including a nicotine replacement therapy portfolio); and Pharmaceutical Services and Active Ingredients (PSAI), which includes API manufacturing and a growing contract development and manufacturing organization (CDMO) business operating through subsidiary Aurigene Pharmaceutical Services Limited. The company's major markets include the United States, India, Russia and CIS countries, Brazil, and Europe. Dr. Reddy's has an extensive pipeline with 80 filings pending USFDA approval and is actively expanding in biosimilars with recent approvals for rituximab and abatacept. The company is also pursuing opportunities in generic semaglutide across multiple international markets. Updated Oct 23, 2026